Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Cancer Research

• Publication date

  2015-03-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-14-3334PMID 25788493
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer diagnosis.

  2015cited by this paper
• TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation

  2014cited by this paper
• Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

  2014cited by this paper
• Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

  2014cited by this paper
• Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.

  2014cited by this paper
• Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer

  2014influential reference
• Prevalence and prognostic significance of TMPRSS2‐ERG gene fusion in lymph node positive prostate cancers

  2014cited by this paper
• GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]

  2013cited by this paper
• ERG Induces Epigenetic Activation of Tudor Domain-Containing Protein 1 (TDRD1) in ERG Rearrangement-Positive Prostate Cancer

  2013cited by this paper
• Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis

  2013cited by this paper
• Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer

  2013cited by this paper
• GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer

  2013cited by this paper
• Prostate-cancer mortality at 11 years of follow-up.

  2012cited by this paper
• Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging.

  2011cited by this paper
• DNA Methylation and the HOXC6 Paradox in Prostate Cancer

  2011cited by this paper
• Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA

  2011cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• Predictive value of PCA3 in urinary sediments in determining clinico‐pathological characteristics of prostate cancer

  2010cited by this paper
• Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test.

  2010cited by this paper
• Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.

  2010cited by this paper
• The Sex-determining region Y-box 4 and homeobox C6 transcriptional networks in prostate cancer progression: crosstalk with the Wnt, Notch, and PI3K pathways.

  2010cited by this paper
• Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort

  2009cited by this paper
• Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer

  2009cited by this paper
• Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes

  2009cited by this paper
• Screening and prostate-cancer mortality in a randomized European study.

  2009cited by this paper
• Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.

  2008cited by this paper
• Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer.

  2008cited by this paper
• Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer

  2007cited by this paper
• PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.

  2007cited by this paper
• APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

  2006cited by this paper
• Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.

  2006cited by this paper
• Rat toxicogenomic study reveals analytical consistency across microarray platforms

  2006cited by this paper
• Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

  2006cited by this paper
• Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis.

  2005cited by this paper
• Loss of HOXC6 expression induces apoptosis in prostate cancer cells

  2005cited by this paper
• Aberrant HOXC expression accompanies the malignant phenotype in human prostate.

  2003cited by this paper
• DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer

  2003cited by this paper
• DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.

  2003cited by this paper
• Multiple functions of Dlx genes.

  2000cited by this paper
• DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.

  1999influential reference
• International Agency for Research on Cancer.

  1985cited by this paper
• Aptima Pca3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer

  year unknowninfluential reference

• Nano-phytochemical-based formulations as promising opportunities for prostate cancer therapy and management: a comprehensive narrative review

  2025cites this paper
• PROSTest, a Multigene Liquid Biopsy Signature, Effectively Stratifies Patients With High PSA for Prostate Biopsy

  2025cites this paper
• Differentiation of high risk prostate cancer with a facile urinary exosome detection workflow

  2025cites this paper
• A hematological and inflammatory marker-based model for prostate carcinoma diagnosis.

  2025cites this paper
• Mechanical characterization of hyaluronic acid-modified cationic liposomes for targeted deliver of ONECUT2 shRNA in hepatocellular carcinoma

  2025cites this paper
• HOXC4 promotes proliferation of endometriotic stromal cells via the SLIT2-ROBO1 axis.

  2025cites this paper
• RNA m1A methyltransferase TRMT61A promotes colorectal tumorigenesis by enhancing ONECUT2 mRNA stability and is a potential therapeutic target

  2025cites this paper
• Urinary biomarkers in cancer detection: explorations, advancements, challenges, and future directions.

  2025cites this paper
• ONECUT2: A Validated Drug Target and Lineage Plasticity Driver in Prostate Cancer and Other Malignancies.

  2025cites this paper
• Molecular Biomarkers for Localized Prostate Cancer: Current Progress and Future Directions.

  2025cites this paper
• NKAIN1 expression relates to the immune evasion and prognosis of gastric cancer

  2025cites this paper
• Established and emerging liquid biomarkers for prostate cancer detection: A review.

  2024cites this paper
• MS4A superfamily molecules in tumors, Alzheimer’s and autoimmune diseases

  2024cites this paper
• Development and validation of the utLIFE-PC algorithm for noninvasive detection of prostate cancer in urine: A prospective, observational study

  2024cites this paper
• Prostate tumor markers: diagnosis, prognosis and management

  2024cites this paper
• Liquid Biomarkers in Prostate Cancer Diagnosis: Current Status and Emerging Prospects

  2024cites this paper
• Prostate cancer genotyping for risk stratification and precision treatment

  2024cites this paper
• Extracellular RNAs from Whole Urine to Distinguish Prostate Cancer from Benign Prostatic Hyperplasia

  2024cites this paper
• Clinicopathological Significances and Prognostic Value of PPFIA4 in Colorectal Cancer

  2023cites this paper
• Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds.

  2023cites this paper
• Gene-Transcript Expression in Urine Supernatant and Urine Cell-Sediment Are Different but Equally Useful for Detecting Prostate Cancer

  2023cites this paper
• The Clinical Usefulness of Prostate Cancer Biomarkers: Current and Future Directions

  2023cites this paper
• Identification of molecular subtypes and a prognostic signature based on chromatin regulators related genes in prostate cancer

  2023cites this paper
• Biomarkers of Aggressive Prostate Cancer at Diagnosis

  2023cites this paper
• Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer

  2023cites this paper
• Tumor-Associated Fibroblast-Derived Exosomal circDennd1b Promotes Pituitary Adenoma Progression by Modulating the miR-145-5p/ONECUT2 Axis and Activating the MAPK Pathway

  2023cites this paper
• Prediction of clinically significant prostate cancer through urine metabolomic signatures: A large-scale validated study

  2023cites this paper
• Microarray image enhancement techniques by denoising: Current status and future directions

  2023cites this paper
• Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification

  2023influential citation
• Cuproptosis signature and PLCD3 predicts immune infiltration and drug responses in osteosarcoma

  2023cites this paper
• Liquid biomarkers for early detection of prostate cancer and summary of available data for their use in African-American men

  2022cites this paper
• Urothelial carcinoembryonic antigen 1 score for early detection of prostate cancer and risk prediction

  2022cites this paper
• Four‐gene signature based on machine learning filtration could predict prognosis of patients with breast cancer

  2022cites this paper
• Bioinformatic investigation and functional analysis of 214 hereditary genes identified non-coding RNAs as therapeautic tool for breast cancer management

  2022cites this paper
• Expression Profiles of HOXC6 Predict the Survival of Glioblastoma Patients and Correlate with Cell Cycle

  2022cites this paper
• Construction of a Comprehensive Diagnostic Scoring Model for Prostate Cancer Based on a Novel Six-Gene Panel

  2022cites this paper
• The involvement of homeobox-C 4 in predicting prognosis and unraveling immune landscape across multiple cancers via integrated analysis

  2022cites this paper
• The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses.

  2022influential citation
• NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ) Prostate Cancer Early Detection Version 1 . 2022 —

  2022cites this paper
• PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer

  2022cites this paper
• Accuracy of novel urinary biomarker tests in the diagnosis of prostate cancer: A systematic review and network meta-analysis

  2022cites this paper
• Prostate cancer biomarkers: a practical review based on different clinical scenarios

  2022cites this paper
• A novel prognostic model for prostate cancer based on androgen biosynthetic and catabolic pathways

  2022cites this paper
• Developing a Multimodal Model for Detecting Higher-Grade Prostate Cancer Using Biomarkers and Risk Factors

  2022cites this paper
• Molecular Biomarkers for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis

  2022influential citation
• Combination of PI-RADS score and mRNA urine test—A novel scoring system for improved detection of prostate cancer

  2022cites this paper
• Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis

  2022cites this paper
• Assessment of Agreement between Two Difference Prostate-Specific Antigen Assay Modalities

  2021cites this paper
• Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder

  2021cites this paper
• Design and Implementation of the Modern Men’s Health Center: A Multidisciplinary Approach

  2021cites this paper
• Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes

  2021cites this paper
• The Role and Significance of Bioumoral Markers in Prostate Cancer

  2021cites this paper
• Derivation and Application of Molecular Signatures to Prostate Cancer: Opportunities and Challenges

  2021cites this paper
• Development of a novel miR-3648-related gene signature as a prognostic biomarker in esophageal adenocarcinoma

  2021cites this paper
• Tumour markers in prostate cancer: The post-prostate-specific antigen era

  2021influential citation
• Blood and urine biomarkers in prostate cancer: Are we ready for reflex testing in men with an elevated prostate-specific antigen?

  2021cites this paper
• Structural model for formation of packages of clinical and diagnostic tests to organize personalized medical care for patients with malignant tumors of the prostate gland

  2021cites this paper
• A Highly Accurate Model for Screening Prostate Cancer Using Propensity Index Panel of Ten Genes

  2021cites this paper
• SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study

  2021cites this paper
• Development of Parallel Reaction Monitoring Assays for the Detection of Aggressive Prostate Cancer Using Urinary Glycoproteins.

  2021cites this paper
• A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers.

  2021cites this paper
• Reference-free transcriptome signatures for prostate cancer prognosis

  2021cites this paper
• MiR‐129‐5p/DLX1 signalling axis mediates functions of prostate cancer during malignant progression

  2021cites this paper
• Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine

  2021cites this paper
• miR-184 delays cell proliferation, migration and invasion in prostate cancer by directly suppressing DLX1

  2021cites this paper
• Urine Biomarkers for Prostate Cancer Diagnosis and Progression

  2021cites this paper
• Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions

  2021cites this paper
• Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men

  2021cites this paper
• Active Surveillance in Prostate Cancer: Role of Available Biomarkers in Daily Practice

  2021cites this paper
• Circulating RNAs in prostate cancer patients.

  2021cites this paper
• Re-Evaluate Fusion Genes in Prostate Cancer

  2021cites this paper
• Characteristics of α2,3‐sialyl N‐glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level

  2021cites this paper
• Can the predictive value of multiparametric MRI for prostate cancer be improved by a liquid biopsy with SelectMDx?

  2021influential citation
• ONECUT2 upregulation is associated with CpG hypomethylation at promoter‐proximal DNA in gastric cancer and triggers ACSL5

  2020cites this paper
• Next-Generation Sequencing in Cancer

  2020cites this paper
• Strategy for prostate cancer patients with low prostate specific antigen level (2.5 to 4.0 ng/ mL)

  2020cites this paper
• Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment

  2020cites this paper
• A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer

  2020cites this paper
• A study of associations between CUBN, HNF1A, and LIPC gene polymorphisms and coronary artery disease

  2020cites this paper
• Emerging role of ONECUT2

  2020cites this paper
• Molecular alterations and precision medicine in prostate cancer

  2020cites this paper
• Clinical utility of emerging biomarkers in prostate cancer liquid biopsies

  2020cites this paper
• Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management

  2020cites this paper
• Prostate Cancer Diagnosis in the Clinic Using an 8-Protein Biomarker Panel.

  2020cites this paper
• Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy

  2020cites this paper
• Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test

  2020cites this paper
• Clinical utility of current biomarkers for prostate cancer detection.

  2020cites this paper
• Biomarkers in the setting of benign prostatic HyperplasiaInduced lower urinary tract symptoms: What an interventional radiologist needs toKnow.

  2020cites this paper
• Identification of genetic biomarkers in urine for early detection of prostate cancer.

  2020cites this paper
• Principal component analysis of RNA-seq data unveils a novel prostate cancer-associated gene expression signature

  2020cites this paper
• Urinary glycoproteins associated with aggressive prostate cancer

  2020cites this paper
• Initial experience with SelectMDx® in the diagnosis of prostate cancer in a real-world evidence clinical practice setting.

  2020cites this paper
• The Clinical Applications of Serum and Urinary Biomarkers in Prostate Cancer

  2020cites this paper
• Personalized strategies in population screening for prostate cancer

  2020cites this paper
• Controversies in Prostate Cancer Diagnosis and Management

  2020cites this paper
• miR-489-3p Inhibits Prostate Cancer Progression by Targeting DLX1

  2020cites this paper
• Concordance and Performance of 4Kscore® and SelectMDx® for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer.

  2020cites this paper
• Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression

  2020cites this paper
• Genome-wide analysis of HOXC4 and HOXC6 regulated genes and binding sites in prostate cancer cells

  2020cites this paper
• Genetic testing for the clinician in prostate cancer

  2020cites this paper